Skip to main content

Table 4 Multivariate Cox proportional hazards models of disease-free survival.

From: Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

 

HR (95% CI)

Pvalue

p53 protein status

Wild-type p53

1

 

Missense

0.773 (0.457-1.308)

0.3366

Truncating

3.213 (1.740-5.935)

0.0002

Number of positive lymph nodes

1-3

1

 

≥ 4

1.992 (1.439-2.758)

< 0.0001

IHC subtypes

Luminal A

1

 

Luminal B

1.237 (0.768-1.992)

0.3812

HER2-positive

2.355 (1.205-4.603)

0.0122

Triple-negative

1.086 (0.580-2.032)

0.7965

  1. CI, confidence index; IHC, immunohistochemistry; HR, hazard ratio.